Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Regeneron Pharmaceutical (REGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 38,913,160
  • Shares Outstanding, K 105,460
  • Annual Sales, $ 4,104 M
  • Annual Income, $ 636 M
  • 36-Month Beta 1.81
  • Price/Sales 9.48
  • Price/Book 8.66

Price Performance

See More
Period Period Low Period High Performance
1-Month
348.82 +5.83%
on 12/07/16
452.96 -18.50%
on 11/14/16
+1.38 (+0.38%)
since 11/08/16
3-Month
325.35 +13.46%
on 11/04/16
452.96 -18.50%
on 11/14/16
-32.68 (-8.13%)
since 09/08/16
52-Week
325.35 +13.46%
on 11/04/16
563.79 -34.52%
on 12/16/15
-187.18 (-33.65%)
since 12/08/15

Most Recent Stories

More News
Should Biotech Investors Worry About Donald Trump?

It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals

Play the Trump Factor with these 4 Large-Cap Stocks

Diversify your portfolio by investing in blue-chip stocks with a proven track record and a certain level of financial strength, resilience & stability.

5 Top Performing Biotechnology Stocks of November

November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.

Buy 7 Stocks with Impressive Interest Coverage Ratio

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

Children's National Health System to Collaborate with the Regeneron Genetics Center in a Large-Scale Whole Exome Sequencing Research Study of Undiagnosed Diseases

Children's National Health System announces the launch of a major three-year research study of undiagnosed diseases in partnership with the Regeneron Genetics Center (RGC, a subsidiary of Regeneron Pharmaceuticals,...

Celgene vs. Regeneron: Which Stock is a Better Pick?

Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola

Focus is back on pipeline and regulatory updates with the end of the third quarter earnings season and elections.

Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Leonard Schleifer, M.D., Ph.D., Founder, President and Chief Executive Officer, and George Yancopoulos, M.D., Ph.D., Founding Scientist,...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 377.37
1st Resistance Point 373.26
Last Price 369.15
1st Support Level 362.27
2nd Support Level 355.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.